Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia

被引:34
作者
Haro, JM
Novick, D
Belger, M
Jones, PB
机构
[1] St Joan Deu Serveis Salut Mental, Res & Dev Unit, Barcelona 08030, Spain
[2] Eli Lilly & Co, European Hlth Outcomes Res, Windlesham, Surrey, England
[3] Eli Lilly & Co, European Commercializat Stat, Windlesham, Surrey, England
[4] Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 2QQ, England
关键词
schizophrenia; antipsychotic agents; treatment outcome; Europe; medication maintenance;
D O I
10.1016/j.eurpsy.2005.12.001
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Antipsychotic medication maintenance and the factors influencing it were analyzed using data from the SOHO study, a large observational study of the outcomes of antipsychotic treatment for schizophrenia in Europe. A total of 7186 adult patients in the outpatient setting who were initiating or changing their antipsychotic medication and who were prescribed only one antipsychotic after the baseline visit were analyzed. Medication maintenance at 12 months varied with the type of antipsychotic prescribed, being highest with clozapine (79.5%) and olanzapine (77.0%), and lowest with quetiapine (51.4%) and amisulpride (58.2%). Multiple logistic regression analysis demonstrated that the type of antipsychotic prescribed at baseline was the most important predictor of medication maintenance. Alcohol dependency, taking mood stabilizers, compulsory admission or arrest in the previous 6 months, greater clinical severity, and changing antipsychotic medication due to lack of effectiveness at baseline predicted a higher frequency of medication discontinuation in the subsequent 12 months. In contrast, medication maintenance was higher among patients who were treatment naive at baseline, socially active or who had loss of libido at baseline. The findings from this study should be interpreted conservatively because of its non-randomized observational design. (c) 2006 Elsevier SAS. All rights reserved.
引用
收藏
页码:41 / 47
页数:7
相关论文
共 28 条
[1]  
AIZENBERG D, 1995, J CLIN PSYCHIAT, V56, P137
[2]   Clozapine in elderly psychiatric patients: Tolerability, safety, and efficacy [J].
Barak, Y ;
Wittenberg, N ;
Naor, S ;
Kutzuk, D ;
Weizman, A .
COMPREHENSIVE PSYCHIATRY, 1999, 40 (04) :320-325
[3]  
Basile VS, 2001, J CLIN PSYCHIAT, V62, P45
[4]   A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse [J].
Beasley, CM ;
Sutton, VK ;
Hamilton, SH ;
Walker, DJ ;
Dossenbach, M ;
Taylor, CC ;
Alaka, KJ ;
Bykowski, D ;
Tollefson, GD .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (06) :582-594
[5]   Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials [J].
Chakos, M ;
Lieberman, J ;
Hoffman, E ;
Bradford, D ;
Sheitman, B .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (04) :518-526
[6]   A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia [J].
Csernansky, JG ;
Mahmoud, R ;
Brenner, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (01) :16-22
[7]   Sexual dysfunction and antipsychotic treatment [J].
Cutler, AJ .
PSYCHONEUROENDOCRINOLOGY, 2003, 28 :69-82
[8]   Old versus new: weighing the evidence between the firstand second-generation antipsychotics [J].
Davis, JM ;
Chen, N .
EUROPEAN PSYCHIATRY, 2005, 20 (01) :7-14
[9]  
Davis JM, 2003, J CLIN PSYCHIAT, V64, P24
[10]  
Droulout T, 2003, ENCEPHALE, V29, P430